Clearside Biomedical Q2 EPS $(0.15) Misses $(0.14) Estimate, Sales $1.02M Beat $120.00K Estimate
Portfolio Pulse from totan@benzinga.com
Clearside Biomedical (NASDAQ:CLSD) reported Q2 losses of $(0.15) per share, missing the analyst consensus estimate of $(0.14) by 7.14%. This is a 15.38% decrease over losses from the same period last year. However, the company reported quarterly sales of $1.02 million, beating the analyst consensus estimate of $120.00 thousand by 748.33%, a 165.10% increase over sales from the same period last year.
August 14, 2023 | 8:11 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Clearside Biomedical's Q2 earnings per share missed estimates, but sales significantly exceeded expectations.
While the company's earnings per share missed estimates, indicating potential issues with profitability, the significant beat on sales suggests strong demand for the company's products. This mixed result could lead to neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100